Sign in Subscribe
College faculty

New Study Reveals Promising Results for Pegylated Interferon Alpha-2a in Treating Essential Thrombocythemia

Strategic Insights

— 1 min read

Researchers at Ankara University Faculty of Medicine have published a study detailing the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN-a-2a) in patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and polycythemia vera (PV). The study, published in the Ankara Universitesi Tip Fakultesi Mecmuas journal, involved 39 patients who received PEG-IFN-a-2a between 2014 and 2021.

Key Takeaways:

  • The study involved 39 patients with MPNs, 25 of whom had ET, 13 had PV, and 1 had primary myelofibrosis.
  • The average age of the participants was 49 years, ranging from 23 to 71.
  • Most patients (92%) had received at least one prior cytoreductive therapy.
  • The median starting dose of PEG-IFN-a-2a was 126 mcg/week, administered by self-injection.
  • The median duration of treatment was 24 months, with a range of 1-77 months.
  • The overall response rates in patients with PV and ET were 84.6% and 92%, respectively.
  • The most common adverse events observed during the treatment period were fatigue (71%), myalgia (54%), and arthralgia (53%).
  • The study concluded that PEG-IFN-a-2a remains a feasible treatment option, particularly for younger patients who wish to avoid prolonged cytotoxic therapy.
  • The researchers involved in the study included Derya Koyun, Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topcuoglu, Onder Arslan, and Muhit Ozcan.

Statistics:

  • 92% of patients had received at least one prior cytoreductive therapy.
  • The median starting dose of PEG-IFN-a-2a was 126 mcg/week.
  • The median duration of treatment was 24 months.
  • The overall response rates in patients with PV and ET were 84.6% and 92%, respectively.
  • 71% of patients experienced fatigue as an adverse event.
  • 54% of patients experienced myalgia as an adverse event.
  • 53% of patients experienced arthralgia as an adverse event.

Sources:

  • A Real World Study: Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Myeloproliferative Neoplasm. Ankara Universitesi Tip Fakultesi Mecmuas, 2025,78(1):60-68.
  • NewsRx. New Essential Thrombocythemia Study Findings Reported from Ankara University Faculty of Medicine (A Real World Study: Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Myeloproliferative Neoplasm). Health & Medicine Week. August 8, 2025; p 2470.

Read more